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Aims In patients with coronary artery disease, the 34C. T variant of the adenosine mono-phosphate
deaminase gene (AMPD1), encoding a dysfunctional protein, predicts improved survival. We hypo-
thesized that in subjects with this variant allele, ischaemia-induced intracellular adenosine formation
is increased, augmenting reactive hyperaemia and ischaemic tolerance.
Methods and results We selected 10 healthy subjects with the CT genotype and 10 CC controls. The
forearm vasodilator response to 2 and 5 min of ischaemia (venous occlusion plethysmography, expressed
as percentage of maximum blood ﬂow after 13 min of ischaemia) was higher in the CT group 56%
(49–74%) and 77% (71–86%) vs. 49% (42–53%) and 60% (55–70%) in the CC group [median (interquartile
range), P ¼ 0.01]. Additionally, ischaemia–reperfusion injury was assessed in the thenar muscle using
99mTc-annexin A5 scintigraphy after forearm ischaemic exercise to detect externalized membrane
phosphatidylserines. At reperfusion, 99mTc-annexin was administered intravenously. The change in
annexin targeting between 1 and 4 h post-injection was 22.3% (interquartile range 22.4 to 21.6%)
in the CT group vs. 20.3% (20.6 to 1.3%) in controls (n ¼ 7 in both groups, P ¼ 0.03).
Conclusion The 34C. T variant of AMPD1 augments vasodilation and reduces tissue injury in response
to forearm ischaemia. These mechanisms could contribute to the survival beneﬁt of cardiovascular
patients with this variant allele.
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Introduction
In patients with heart failure and in those with coronary
artery disease, the presence of the 34C . T polymorphism
on at least one of the alleles encoding for the enzyme ade-
nosine mono-phosphate deaminase (AMPD1) is associated
with prolonged survival.1,2 AMPD is one of the enzymes
involved in the intracellular metabolism of the purine
nucleoside adenosine (Figure 1), catalysing the conversion
of AMP to IMP.3 In humans, four AMPD isoforms have been
described, named after the source from which they were
initially puriﬁed: M (muscle), L (liver), E1, and E2 (erythro-
cytes), encoded by the different genes AMPD1, AMPD2, and
AMPD3.4 Approximately 15–20% of Caucasian and African-
American individuals are heterozygous or homozygous for
the 34C . T variant of AMPD1, encoding a truncated
protein with the loss of function.5
Under conditions of impending tissue danger, such as
ischaemia, the extracellular adenosine concentration rapidly
increases.6 Subsequent stimulation of adenosine receptors
induces various effects such as vasodilation, ischaemic pre-
conditioning, and inhibition of inﬂammation.7 On the basis
of the observation that AMPD activity is signiﬁcantly reduced
in patients heterozygous for the 34C . T variant (CT geno-
type), it was suggested that in these patients during
ischaemia, AMP is preferentially degraded into adenosine,
which will increase ischaemic tolerance.1
We hypothesized that subjects with the 34C. T
variant show augmented reactive hyperaemia and reduced
ischaemia–reperfusion injury in response to ischaemia. To
test this hypothesis, we selected healthy subjects with the
CT genotype and controls homozygous for the common C
allele (CC genotype), with otherwise similar parameters of
adenosine transport and metabolism. The vasodilator response
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to 2, 5, and 13 min of forearm ischaemia was determined by
venous occlusion plethysmography. During the last minute of
the 13 min period of ischaemia, the subjects also performed
rhythmic contractions of the hand, because this stimulus has
previously been demonstrated to induce maximum vasodila-
tion, which is dependent only on the structural characteristics
of the vessel wall.8 We hypothesized that subjects with the
34C. T variant of AMPD1 have higher forearm blood ﬂow
(FBF) responses to 2 and 5 min of ischaemia, but not to
13 min of ischaemia. This experiment was repeated in the pre-
sence of dipyridamole, as a pharmacological tool to inhibit
facilitated diffusion of adenosine through the equilibrative
nucleoside transporter (ENT), to explore the role of increased
intracellular adenosine formation. We hypothesized that dipyr-
idamole potentiates reactive hyperaemia, as previous evi-
dence suggests that during ischaemia, transport of adenosine
over the cellular membrane is mainly from outside the cell
inwards.9,10 This effect of dipyridamole, however, is expected
to be less pronounced in subjects with the CT genotype,
because in these subjects, impaired conversion of AMP to
IMP will enhance the intracellular adenosine formation, thus
decreasing the transmembranous adenosine concentration
gradient, which is the driving force for adenosine transport.11
In an additional series of experiments, ischaemia–
reperfusion injury was determined in the thenar muscle,
using 99mTc-annexin A5 scintigraphy to detect phosphatidyl-
serine exposure on cellular membranes of affected cells as
early marker of ischaemic injury, as described previously.12
Methods
Subjects
The study protocol was approved by the Institutional Review Board
of the Radboud University Nijmegen Medical Centre. Ninety-six
healthy subjects participated after signing informed consent.
Blood was drawn for genotyping of the AMPD1 and adenosine A2A
receptor genes (ADORA2A) and for the determination of the activi-
ties of the ENT, adenosine kinase, and adenosine deaminase. The
ADORA2A 1976C. T genotype was determined, as the TT variant
could potentially affect its function.13 From these volunteers, sub-
jects were selected to participate in the current study or another
study on the effect of the 1976C. T polymorphism in ADORA2A.
Twenty subjects had the CT genotype and two the TT genotype
for AMPD1. To study reactive hyperaemia, we selected 10 subjects
with the CT genotype and 10 control subjects with the CC genotype,
with comparable sex, age, and body mass index. To assess tolerance
to ischaemia–reperfusion injury, we selected seven male subjects
with the CT genotype and seven controls (Table 1).
Post-occlusive reactive hyperaemia
Experiments were performed in a temperature-controlled room
(238C) in the morning after an overnight fast and 24 h of caffeine
abstinence. The brachial artery of the non-dominant arm was can-
nulated with a 20-gauge catheter for intra-arterial drug adminis-
tration and blood pressure recording. FBF was recorded
simultaneously on both arms by venous occlusion plethysmography
using mercury-in-silastic strain gauges.14 Before each recording, a
wrist cuff was inﬂated to 200 mmHg to exclude the hand circulation.
Arterial occlusion of the non-dominant forearm was induced by
inﬂation of an additional upper arm cuff to 200 mmHg.
Thirty minutes after insertion, FBF was recorded for 5 min during
saline infusion (baseline FBF). Subsequently, the FBF response to 2,
5, and 13 min of forearm ischaemia was measured for 3, 5, and
5 min, respectively, as described previously.15 During the last
minute of the 13 min period of ischaemia, the subjects performed
rhythmic handgripping, as a stimulus for maximal forearm vasodila-
tion.8 After 40 min of equilibration, this experiment was repeated,
but now during concomitant administration of dipyridamole (Persan-
tinw, Boehringer Ingelheim, Espana SA, Spain) into the brachial
artery (7.4 nmol/min/dL of forearm tissue). A previous study
demonstrated that this dose does not affect baseline FBF, but signiﬁ-
cantly potentiates adenosine-induced vasodilation.16 Administration
of dipyridamole was discontinued 10 s after initiation of forearm
occlusion and restarted 10 s before reperfusion. After 30 min of
equilibration, the FBF response to intrabrachial administration of
sodium nitroprusside (SNP; 0.06 and 0.6 mg/min/dL; Pharmacy
Radboud University Nijmegen Medical Centre) and acetylcholine
(ACh; 0.5 and 2.0 mg/min/dL; miocholw-E, Novartis, Bournonville
Pharma BV, The Hague, The Netherlands) was recorded for 5 min
per dose to study endothelium-independent and endothelium-
dependent vasodilation, respectively.
Ischaemia–reperfusion injury
Circulation to the non-dominant forearm was interrupted for 10 min
by inﬂation of an upper arm cuff to 200 mmHg. Concomitantly, sub-
jects performed rhythmic isometric handgripping with a dynamo-
meter at 50% of maximum force, alternating 5 s of contraction
and 5 s of relaxation until exhaustion. Immediately on reperfusion,
99mTc-annexin A5 was administered intravenously into the dominant
arm. At 1 and 4 h post-injection, both hands were scanned
simultaneously until 150 000 counts were detected (or when a
maximum scanning time of 25 min was reached) using a gamma
camera equipped with a low-energy high-resolution collimator
(Siemens Orbiter, Hoffman Estates, IL, USA) connected to a
Hermes Gold image processing system (Nuclear Diagnostics, Stock-
holm, Sweden) as previously described.12
Genetic analysis
Blood was drawn in EDTA-containing vacutainers and stored at
2708C until DNA isolation. Genomic DNA isolation was performed
using a standard desalting protocol.17 Genotyping was performed
by pyrosequencing according to the protocol of the manufacturer
(Pyrosequencing AB, Uppsala, Sweden).18
For genotyping of the AMPD1 34C . T variant, the following
reaction was carried out: primers FW8076 (50-gcaatctacatg-
tgtctacc-30, 10 pmol) and RV8077 (50-agcgctgctccggttcatagattatagcc
Figure 1 Schematic representation of the formation, transport, and degra-
dation of adenosine. ADA, adenosine deaminase; AK, adenosine kinase; IMP,
inosine mono-phosphate; 50-NT, 50-nucleotidase.
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atgtttctgaatta-30, 1 pmol) were combined with a biotinylated universal
primer (4205: 50Biotin-gctgctccggttcatagatt-30, 9 pmol), 50 ng of DNA,
0.32 mM dNTPs, 0.5 U Taq DNA polymerase (Invitrogen, Breda, The
Netherlands), and a PCR buffer containing 60 mM Tris–HCl pH 8.5,
15 mM ammonium sulfate, and 1.5 mM MgCl2 in a total volume of
25 mL. For genotyping of the ADORA2A 1976C. T variant, the following
ampliﬁcation reaction was carried out: primers FW8073 (50-gacggga-
caccgctgatcgtttacggagg cccaatggcta-30, 1 pmol) and RV8074 (50-cc
caacgtgactggtcaag-30, 10 pmol) were combined with a biotin-labelled
universal primer (4206: 50Biotin-gggacaccgctgatcgttta-30, 9 pmol),
50 ng DNA, 0.32 mM dNTPs, 0.5 U Taq DNA polymerase (Invitrogen),
and a PCR buffer containing 10 mM Tris–HCl pH 8.0, 50 mM KCl, 0.1%
Triton X-100 (v/v), 0.015% gelatin (w/v), 5% DMSO (v/v), and 1.5 mM
MgCl2 in a volume of 25 mL. The cycling conditions for both ampliﬁca-
tion reactions were similar, starting with 5 min at 928C, followed by
39 cycles (35 in the case of ADORA2A) of 1 min at 928C, 1 min at the
optimized annealing temperature (558C for AMPD1 and 548C for
ADORA2A), and 1 min at 728C, then followed by an extra 5 min at
728C. The ampliﬁcations were performed in a PTC-200 Multicycler
(MJ-Research via Biozym, Landgraaf, The Netherlands).
Pyrosequencing for AMPD1 was performed in a forward assay using
primer 8078 (50-tcatacagctgaagagaaa-30) and that for ADORA2A in a
reverse assay using primer 8075 (50-ctcaccagcccca-30).
Laboratory analysis
In isolated erythrocytes, uridine uptake was determined as described
previously.19 Vmax and Km values for the ENTwere estimated accord-
ing to Michaelis–Menten kinetics. For the determination of adeno-
sine deaminase activity, adenosine was added to erythrocyte lysate
in Tris-buffer (0.35% erythrocytes) in a ﬁnal concentration of 25,
50, 100, 200, and 300 mmol/L at 378C. After 15 min, 50 mL 1.5 M
HClO4 was added, and the solution was placed on ice. After centrifu-
gation, 0.5 M trioctylamine in chloroform was added to the super-
natant in equal volumes. Finally, after centrifugation, the
neutralized supernatant was used for the detection of inosine and
hypoxanthine with reversed-phase HPLC using tetrabutylammonium
hydrogen sulfate (10 mM) as the ion-pair forming agent (pH 6.0) with
UV detection set at 254 nm. The sum of inosine and hypoxanthine
was used for the calculation of Vmax and Km for adenosine deaminase.
For the determination of adenosine kinase activity, adenosine was
added to 10 mL lysate in 43 mL distilled water, 2 mL 50 mM MgCl,
2 mL 100 mM DTT, 2 mL 50 mM GTP, 0.7 mL 3 mM erythro-9-
(2-hydroxynon-3-yl)-adenine (EHNA), and 100 mL Tris-buffer in a
ﬁnal concentration of 0.1, 0.2, 0.5, 1, and 2 mmol/L at 378C. After
3.5 min, 50 mL 1.5 M HClO4 was added, and the solution was placed
on ice. After centrifugation, 100 mL 0.5 M trioctylamine in chloroform
was added to 150 mL supernatant. Finally, after centrifugation, the
AMP concentration in the supernatant was measured with reversed-
phase HPLC using tetrabutylammonium hydrogen sulfate (10 mM) as
the ion-pair forming agent (pH 7.7) with UV detection set at
260 nm. The increase in AMP was used to calculate Vmax and Km
values. Plasma caffeine concentration was determined by reversed-
phase HPLC with UV detection set at 273 nm.20 All measurements
were performed in duplicate.
Preparation of 99mTc-HYNIC-annexin A5
99mTc-HYNIC-annexin A5 was prepared as described previously.21
Brieﬂy, recombinant human annexin A5 (kindly provided by Dr Van-
derheijden, Theseus Imaging Corporation, Boston, MA, USA) was
conjugated with succinimidyl-hydrazinonicotinic acid (HYNIC).
About 100 mg samples of the annexin-HYNIC conjugate in 500 mL
113 mM tricine, pH 6.8, were stored at 2208C. Before each experi-
ment, 99mTc-Pertechnetate (500 MBq) was added to the 100 mg
sample of the annexin-HYNIC conjugate in the presence of 50 mg
stannous sulfate. About 400 MBq 99mTc-annexin A5 was administered
to each subject.
Statistical analysis
As not all variables showed a Gaussian distribution, we present the
data as median and interquartile range, and we used Wilcoxon and
Koziol tests to evaluate differences. All tests were two-sided and a
result with P, 0.05 was considered statistically signiﬁcant. The
primary tests in two different studies were on the difference in
vasodilator response and in annexin targeting, respectively. The
effect of dipyridamole on reactive hyperaemia in the ﬁrst study
was a secondary endpoint, which only served to support the main
ﬁndings, and the P-values of this analysis should be interpreted
Table 1 Baseline characteristics of the two groups in both studies [median (interquartile range)]; there are no signiﬁcant differences
between the CT and CC groups
Characteristics Plethysmography study Scintigraphy study
CT genotype CC genotype CT genotype CC genotype
Number (male/female) 10 (7/3) 10 (7/3) 7 (7/0) 7 (7/0)
Age (years) 22 (21–25) 23 (22–25) 24 (21–28) 22 (20–26)
Body mass index (kg/m2) 22 (20–24) 22 (21–24) 24 (20–25) 22 (20–24)
SBP (mmHg) 126 (118–131) 128 (120–130) 128 (118–136) 128 (128–128)
DBP (mmHg) 68 (66–77) 72 (67–80) 76 (70–92) 72 (62–80)
Heart rate (b.p.m.) 71 (68–76) 76 (64–77) 68 (60–76) 72 (60–76)
Plasma glucose (mmol/L) 4.9 (4.3–5.3) 4.9 (4.1–5.3) 5.1 (4.7–5.5) 4.9 (4.3–5.3)
Cholesterol (mmol/L) 4.4 (3.5–5.2) 4.1 (3.6–4.6) 4.0 (3.2–4.6) 4.1 (3.8–4.5)
Plasma caffeine (mg/L) 0.0 (0.0–0.5) 0.0 (0.0–0.2) 0.1 (0.0–0.2) 0.0 (0.0–0.1)
Uridine uptake
Km (mM) 169 (153–201) 171 (158–213) 202 (160–207) 167 (158–211)
Vmax (nmol/min/mg) 269 (233–311) 286 (261–306) 306 (217–319) 277 (253–298)
AK activity
Km (mM) 0.41 (0.36–0.54) 0.48 (0.42–0.62) 0.53 (0.40–0.54) 0.56 (0.49–0.80)
Vmax (nmol/min/mg) 24 (20–38) 26 (19–35) 25 (21–34) 33 (19–35)
ADA activity
Km (mM) 44 (40–47) 44 (40–47) 42 (40–47) 45 (39–46)
Vmax (nmol/min/mg) 70 (46–104) 66 (56–76) 74 (53–95) 66 (51–73)
ADORA2A 1976 genotype 9 CT/1 CC 9 CT/1 CC 3 CT/3 CC/1 TT 4 CT/3 CC
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with some caution, as we applied no correction for multiple testing.
Analysis of the FBF responses was performed off-line blinded for the
speciﬁc AMPD1 genotypes. For each post-occlusive period, the
highest FBF was selected. The FBF response to 2 and 5 min of ischae-
mia was expressed as percentage of maximum FBF after 13 min of
ischaemia. A Koziol test was used to compare these responses
between both genotype groups. The effect of dipyridamole on FBF
responses to 2 and 5 min of ischaemia was expressed as percentage
increase, and a Koziol test was used to compare both genotype
groups.
In the second study, all digital scintigraphic images were analysed
off-line by the same blinded investigator (W.J.G.O.), using Hermes
Gold software. Region-of-interest analysis was performed for the
thenar muscle region, as described previously.12 Radioactivity was
expressed as counts per pixel. To correct for background activity,
the targeting of annexin was expressed as the percentage difference
between the experimental and control hand, and the results were
expressed as the change in targeting between 1 and 4 h post-
reperfusion, as described previously.12
Results
Vmax and Km values of adenosine deaminase, adenosine
kinase, and the ENT did not differ between both groups,
and ADORA2A genotype frequencies were equally distribu-
ted (Table 1).
Post-occlusive reactive hyperaemia
Baseline FBF did not signiﬁcantly differ between both groups
[2.1 (1.7–2.6) mL/min/dL of forearm tissue in the CT geno-
type group and 2.2 (1.7–2.9) mL/min/dL in the CC group;
P ¼ 0.8]. In addition, maximum vasodilation in response to
13 min of ischaemia did not differ between the groups
[38.5 (31.9–46.0) mL/min/dL in the CT group vs. 40.5
(32.4–51.3) mL/min/dL in the CC group; P ¼ 0.5]. FBF in
response to the 2 and 5 min period of ischaemia was
higher in the CT genotype group when compared with the
controls (Figure 2, P ¼ 0.01). There were no differences in
FBF in the control arm and mean arterial pressure
between both groups.
The effect of administration of dipyridamole on baseline
FBF was not different between both groups [from 2.1 (1.4–
2.7) to 2.3 (1.4–3.0) mL/min/dL in the CT genotype group
and from 2.0 (1.4–2.5) to 2.4 (2.0–3.1) mL/min/dL in the
CC group; P ¼ 0.4]. Dipyridamole signiﬁcantly potentiated
FBF responses to 2 and 5 min of ischaemia in the control
group [FBF 25.2 (19.9–32.4) and 35.5 (31.2–42.1) mL/min/
dL during dipyridamole infusion after 2 and 5 min of ischae-
mia, respectively, P ¼ 0.02 and 0.005 vs. FBF without
dipyridamole], but not in the CT genotype group [FBF 27.4
(21.5–32.3) and 31.9 (29.5–40.0) mL/min/dL during dipyri-
damole administration after 2 and 5 min of ischaemia, P ¼
0.2 and 0.1 vs. FBF without dipyridamole, respectively].
The effect of dipyridamole was more pronounced in the CC
genotype group than in the CT group (Figure 3, P ¼ 0.01).
Finally, SNP- and ACh-induced vasodilation did not differ
between both groups. Administration of SNP increased FBF
from 2.8 (1.7–3.3) mL/min/dL at baseline to 7.3 (4.6–8.0)
and 14.6 (11.5–19.8) mL/min/dL in subjects with the CT
genotype and from 2.5 (2.0–3.2) mL/min/dL to 6.4 (5.2–
8.7) and 11.6 (8.9–21.7) mL/min/dL in the CC control
group (P ¼ 0.8). Administration of ACh increased FBF from
3.1 (2.4–4.9) mL/min/dL at baseline to 6.8 (3.6–9.1) and
9.9 (5.2–12.3) mL/min/dL in subjects with the CT genotype
and from 3.2 (2.7–3.9) mL/min/dL to 6.8 (5.2–11.4) and 8.2
(6.2–15.3) mL/min/dL in the CC control group (P ¼ 1.0).
Ischaemia–reperfusion injury
There was no difference in the duration of ischaemic exer-
cise [140 (130–190) s in the CT genotype group vs. 170
(125–180) s in the controls, P ¼ 0.7] and maximum contrac-
tile force [50 (46–72) kg in the CT genotype group vs. 48
(40–52) kg in controls, P ¼ 0.3] between both groups.
Annexin targeting was less in the CT genotype group than
in CC controls (Figure 4; P ¼ 0.03).
Discussion
The results of the present study demonstrate that in sub-
jects with the 34C . T variant of AMPD1, reactive hyper-
aemia in response to forearm ischaemia is enhanced and
tissue injury is reduced. These mechanisms could well con-
tribute to the reduced cardiovascular mortality in patients
with genotypes containing the variant allele.
Figure 2 Box plot of the FBF responses to 2 and 5 min of ischaemia,
expressed as percentage of maximum FBF. P ¼ 0.01 for comparison
between both groups.
Figure 3 Box plot of the effect of administration of dipyridamole on the FBF
responses to 2 and 5 min of ischaemia, expressed as percentage increase
when compared with the FBF response without dipyridamole. P ¼ 0.01 for
comparison between both groups.
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Previous studies have shown that the 34C. T variant of
AMPD1 is associated with improved survival in patients
with heart failure1 and in those with coronary artery
disease.2 Also in cardiac donors, the 34C . T variant
appears to protect against acute heart failure.22 It is
unknown which mechanism is responsible for these ben-
eﬁcial cardiovascular effects. The C!T transition results
in a nonsense mutation encoding a truncated AMPD
protein.5 AMPD activity in human muscle biopsies is
30–40% of normal in subjects with the CT genotype and
,2% in subjects homozygous for the variant allele.23
Although predominantly expressed in skeletal muscle,
AMPD1 is also expressed in cardiomyocytes and aorta.3
Indeed, also in cardiac tissue, AMPD activity is 50%
reduced in patients with the CT genotype.24 Considering
the various beneﬁcial cardiovascular effects of adenosine
receptor stimulation, it is logical to assume that in subjects
with AMPD deﬁciency, ischaemia-induced adenosine for-
mation and subsequent adenosine receptor stimulation are
potentiated, provided that alternative routes of adenosine
metabolism are unchanged (Figure 1) and that this mechan-
ism is responsible for the improved cardiovascular outcome.
In the present study, we focused on reactive hyperaemia,
because previous studies demonstrated that reactive hyper-
aemia is, at least partially, mediated by adenosine receptor
stimulation.25 We postulated that a higher reactive hyper-
aemia in subjects with the 34C . T variant of AMPD1
indicates increased adenosine receptor stimulation. In
addition, the enhanced reactive hyperaemia itself could
also have beneﬁcial effects on recovery after an ischaemic
insult.26,27 This mechanism was already suggested by
recent preliminary data in healthy volunteers with the
34C . T variant, which demonstrated augmented reactive
hyperaemia in the forearm, but only in the second minute
after reperfusion, and after correction for per cent body
fat.28 In line with these observations, we showed that reac-
tive hyperaemia in response to 2 and 5 min of ischaemia is
augmented in subjects with the CT genotype, compared
with a control group, with otherwise similar activities of
adenosine deaminase, adenosine kinase, and the ENT and
with similar ADORA2A genotype frequencies. The groups
did not differ in endothelial function. The observation that
reactive hyperaemia in response to a stimulus for
maximum forearm vasodilation was similar between both
groups excludes that structural changes of the vessel wall
account for the observed differences. Moreover, we cor-
rected for possible structural differences by expressing the
FBF responses as percentage of maximum FBF in each
subject.
We assume that this augmented reactive hyperaemia is
mediated by increased adenosine receptor stimulation.
Unfortunately, it is extremely difﬁcult to reliably measure
adenosine concentrations in humans in vivo, because of the
short half-life of adenosine in blood (,1 s)29 and because
the endothelium acts as a highly active metabolic barrier
for adenosine.30 Therefore, the concentration of adenosine
in blood does not reﬂect that of adenosine in the vicinity of
adenosine receptors on several cell types, such as endothelial
cells, cardiomyocytes, and vascular smooth muscle cells.
Several studies have demonstrated that during strenuous
exercise, the tissue adenosine concentration in skeletal
muscle biopsies is increased in subjects with the CT genotype
when compared with controls, but there are no data on the
extracellular adenosine concentration during exercise or
ischaemia in these subjects.23,31 Because of these difﬁculties
in measuring adenosine concentration, we previously vali-
dated dipyridamole as a pharmacological tool to inhibit the
ENT. We demonstrated that systemic administration of dipyr-
idamole (administered orally) signiﬁcantly inhibits ex vivo
adenosine uptake in isolated erythrocytes.19 Secondly,
during concomitant administration of adenosine into the bra-
chial artery, administration of dipyridamole increased the
adenosine concentration in the venous efﬂuent (as measured
with microdialysis).32 Thirdly, in the same dose as in the
present study, dipyridamole did not affect baseline vascular
tone, but signiﬁcantly potentiated the vasodilator response
to the intrabrachial administration of adenosine.33 Finally,
the vasodilator response to intrabrachial administration of
dipyridamole and the haemodynamic responses to the sys-
temic administration of dipyridamole could signiﬁcantly be
reduced by adenosine receptor antagonists.16,34 In the
present study, we used this property of dipyridamole to
explore the contribution of facilitated adenosine transport
to the observed difference in reactive hyperaemia between
subjects with the CT genotype and controls.
It is well known that during ischaemia, the extracellular
adenosine concentration rapidly increases.6,35 In the present
study, dipyridamole potentiated reactive hyperaemia in
both groups (although this was not signiﬁcant for the CT
genotype group). This ﬁnding indicates that during ischaemia
and early reperfusion, ﬂux of adenosine over the cellular
membrane is mainly directed inwards. In subjects with the
CT genotype, the effect of dipyridamole on maximum reac-
tive FBF was less than in controls. This observation suggests
that in these subjects, during ischaemia and early reperfu-
sion, the transmembranous adenosine gradient is less than
in control subjects. This is compatible with the view that
during ischaemia in subjects with decreased activity of the
cytosolic AMPD enzyme, intracellular—and not extracellu-
lar—formation of adenosine from AMP is increased.
Adenosine receptor stimulation increases resistance to
ischaemia–reperfusion by several mechanisms.36 We hypo-
thesized that in patients with the 34C . T AMPD1 variant,
augmented adenosine formation during ischaemia not
only augments reactive hyperaemia, but also reduces
ischaemia–reperfusion injury. To test this hypothesis, we
used 99mTc-annexin A5 scintigraphy to determine
Figure 4 Box plot of the difference in annexin targeting between 1 and 4 h
post-reperfusion. P ¼ 0.03 for comparison between the groups.
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ischaemia–reperfusion injury in thenar muscle. We demon-
strated that ischaemia–reperfusion injury is attenuated in
subjects with the 34C . T genotype. 99mTc-annexin A5 scin-
tigraphy is based on the high-afﬁnity binding of annexin A5
to phosphatidylserine residues on cellular membranes. It is
well documented that loss of membrane asymmetry is an
early general feature of apoptosis, resulting in externaliza-
tion of phosphatidylserine residues in affected cells, thus
providing binding sites for annexin A5.37 Alternatively,
some previous studies have demonstrated that phosphatidyl-
serine exposure could be a reversible event, preceding com-
mitment to apoptotic cell death.38 By labelling recombinant
annexin A5 with 99mtechnetium, it is possible to detect these
cellular changes in vivo with a gamma camera.39 In previous
studies, we validated 99mTc-annexin A5 scintigraphy as a
sensitive model to detect ischaemia–reperfusion injury in
skeletal muscle and demonstrated that this injury could be
reduced by the administration of adenosine and dipyrida-
mole prior to the ischaemic insult.12,19 Additionally, we
demonstrated that the adenosine receptor antagonist caf-
feine abolishes protection by ischaemic preconditioning.21
Several potential limitations of our study should be
addressed. First, we only studied subjects who were hetero-
zygous for the 34C . T variant. In subjects with the TT gen-
otype, reactive hyperaemia and ischaemic tolerance could
be augmented even more. Secondly, for technical reasons,
we did not measure plasma adenosine concentrations.
However, the observation that the effect of dipyridamole
on reactive hyperaemia was less in subjects with the CT
genotype provides evidence that indeed intracellular adeno-
sine formation during ischaemia is enhanced in these
subjects. Thirdly, we did not determine activities of endo-
and ecto-50-nucleotidase, which is also important in the
formation of adenosine (Figure 1). Finally, we studied the
response to ischaemia in the forearm and not in the heart.
However, the 34C . T variant of AMPD1 also reduces AMPD
activity in cardiac tissue.24
In conclusion, we demonstrated that the 34C . T variant
of the AMPD1 gene augments post-occlusive reactive
hypaeremia and tolerance to ischaemia–reperfusion. The
reduced potentiating effect of dipyridamole on reactive
hyperaemia in subjects with the CT genotype indicates
that the AMPD1 gene determines the effect of dipyridamole
and supports the concept that the transmembranous adeno-
sine concentration gradient during ischaemia is diminished
in these subjects, which is compatible with increased intra-
cellular formation of adenosine during ischaemia. Our obser-
vations predict that in trials with ENT inhibitors designed to
explore the protective effect of endogenous adenosine
against ischaemia–reperfusion injury, most beneﬁt is
expected in patients without the 34C . T variant allele.
The augmented reactive hyperaemia and increased ischae-
mic tolerance could contribute to the previously observed
improved survival in cardiovascular patients with this
variant allele and bridge the gap between the rational
theoretical concept of adenosinergic cardiovascular protec-
tion and previous epidemiological observations.
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